First-in-human study of E7130 (a tumor microenvironment-ameliorating microtubule inhibitor) in patients with advanced solid tumors: Primary results of the dose-escalation part.
Sign Up to like & getrecommendations! Published in 2023 at "Cancer"
DOI: 10.1002/cncr.34788
Abstract: BACKGROUND E7130 is a novel anticancer agent created from a total synthetic study of norhalichondrin B. The authors report the E7130 dose-escalation part of a first-in-human study of patients with advanced solid tumors (NCT03444701). METHODS… read more here.
Keywords: dose escalation; group; escalation part; study ... See more keywords
First‐in‐Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742, a Dual Antagonist of Toll‐like Receptors 7 and 8, in Healthy Volunteers
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1176
Abstract: The first‐in‐human phase I study for E6742, a dual toll‐like receptor (TLR) 7 and TLR8 antagonist, has been conducted to assess the safety, tolerability, and pharmacokinetics of E6742 in healthy volunteers. In a single ascending… read more here.
Keywords: toll like; e6742 dual; safety; tolerability ... See more keywords
Confirmation of the Cardiac Safety of PGF2α Receptor Antagonist OBE022 in a First‐in‐Human Study in Healthy Subjects, Using Intensive ECG Assessments
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.447
Abstract: OBE022, a new orally active prostaglandin F2α receptor antagonist (OBE022) with myometrial selectivity is being developed to reduce uterine contractions during preterm labor. This first‐in‐human study evaluated the effect of OBE022 following multiple doses on… read more here.
Keywords: receptor antagonist; study; effect; human study ... See more keywords
A FIRST‐IN‐HUMAN TRIAL OF THE NOVEL MULTI‐ACTION THERAPY TINOSTAMUSTINE (EDO‐S101) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) HODGKIN LYMPHOMA (HL)
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.137_2630
Abstract: (95% CI: 5.0 days-1.9 months; Fig. 1). At a median follow up of 4.15 years 6 patients treated at target dose were still alive and treatment-free, whereas the 13 patients treated at lower dose levels… read more here.
Keywords: novel multi; trial novel; action therapy; first human ... See more keywords
First‐in‐human intracochlear application of human stromal cell‐derived extracellular vesicles
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Extracellular Vesicles"
DOI: 10.1002/jev2.12094
Abstract: Abstract Extracellular vesicles (EVs) derived from the secretome of human mesenchymal stromal cells (MSC) contain numerous factors that are known to exert anti‐inflammatory effects. MSC‐EVs may serve as promising cell‐based therapeutics for the inner ear… read more here.
Keywords: extracellular vesicles; intracochlear application; msc evs; evs ... See more keywords
A Randomized First‐in‐Human Study With UB‐312, a UBITh® α‐Synuclein Peptide Vaccine
Sign Up to like & getrecommendations! Published in 2022 at "Movement Disorders"
DOI: 10.1002/mds.29016
Abstract: α‐Synuclein (αSyn) is believed to play a central role in Parkinson's disease (PD) neuropathology and is considered a target for disease modification. UB‐312 is a synthetic αSyn peptide conjugated to a T helper peptide and… read more here.
Keywords: randomized first; study 312; peptide; 312 ubith ... See more keywords
First-in-human evaluation of [11C]PS13, a novel PET radioligand, to quantify cyclooxygenase-1 in the brain
Sign Up to like & getrecommendations! Published in 2020 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-020-04855-2
Abstract: This study assessed whether the newly developed PET radioligand [11C]PS13, which has shown excellent in vivo selectivity in previous animal studies, could be used to quantify constitutive levels of cyclooxygenase-1 (COX-1) in healthy human brain.… read more here.
Keywords: 11c ps13; human evaluation; pet radioligand; first human ... See more keywords
Intraluminal flexible sheath for the protection of low anastomosis after anterior resection: results from a First-In-Human trial on 15 patients
Sign Up to like & getrecommendations! Published in 2019 at "Surgical Endoscopy"
DOI: 10.1007/s00464-019-07279-8
Abstract: Defunctioning ostomy is commonly used to protect patients from anastomotic leakage complications after low anterior resection, but is fraught with its own deleterious effects. This first-in-human study examines the safety and preliminary efficacy of Colovac,… read more here.
Keywords: protection; anastomosis; first human; sheath ... See more keywords
First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies
Sign Up to like & getrecommendations! Published in 2022 at "Investigational New Drugs"
DOI: 10.1007/s10637-022-01217-7
Abstract: Purpose. Sym013 contains six humanized monoclonal antibodies that bind to non-overlapping epitopes on three human epidermal growth factor receptors (HER1-3). Preclinical studies suggested Sym013 strongly suppresses growth of multiple epithelial tumors. This is a first-in-human… read more here.
Keywords: exploring safety; advanced epithelial; trial; epithelial malignancies ... See more keywords
First in Human Evaluation and Dosimetry Calculations for Peptide 124I-p5+14—a Novel Radiotracer for the Detection of Systemic Amyloidosis Using PET/CT Imaging
Sign Up to like & getrecommendations! Published in 2021 at "Molecular Imaging and Biology"
DOI: 10.1007/s11307-021-01681-2
Abstract: Accurate diagnosis of amyloidosis remains a significant clinical challenge and unmet need for patients. The amyloid-reactive peptide p5+14 radiolabeled with iodine-124 has been developed for the detection of amyloid by PET/CT imaging. In a first-in-human… read more here.
Keywords: detection; pet imaging; amyloidosis; dosimetry ... See more keywords
First-in-Human Phase I Study of Nicotinamide-Expanded Related Donor Natural Killer Cells for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma and Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2019 at "Biology of Blood and Marrow Transplantation"
DOI: 10.1016/j.bbmt.2018.12.317
Abstract: Background Adoptive transfer of cytolytic natural killer (NK) cells is limited by the short-term persistence of NK cells and their impaired effector function after infusion. We have previously shown that ex-vivo expansion of NK cells… read more here.
Keywords: blood; first human; natural killer; lymphoma ... See more keywords